Ripped 250 Royal Pharmaceuticals

Article: CG-0005
Out of stock
In stock
0,00
69,00
+
Shipping methods
  • Pickup from New Mail
  • New Mail Courier
  • Pickup from the store
  • Other transport services
Payment methods
  • Cash upon receipt
  • Bank transfer
  • Privat 24
  • WebMoney
Description
  • Category: Injectable Anabolic-Androgenic Steroid Blend (Research Only)
  • Brand: Royal Pharmaceuticals
  • Strength: 250 mg/ml total (Test P 100 mg, Mast P 50 mg, Tren A 50 mg)
  • Packing: 10 1 ml ampoules
  • Origin: United Kingdom
  • Use Notice: For laboratory and analytical research only — not for human or veterinary administration.

What is Ripped 250?

Ripped 250 is a fixed-combination injectable consisting of three short-acting anabolic–androgenic steroid esters:

  • Testosterone Propionate – 100 mg
  • Drostanolone Propionate (Masteron P) – 50 mg
  • Trenbolone Acetate – 50 mg

Short-chain esters create rapid release from the intramuscular depot, making this blend suitable for research requiring frequent sampling intervals or tight control of androgen exposure.

Key Technical Characteristics

  • Pharmacological class: Anabolic-androgenic steroids (AAS)
  • Route: Intramuscular injection
  • Ester types: Propionate (Test/Mast) and acetate (Tren)
  • Approximate half-lives: Test P ~2 days, Mast P ~2 days, Tren A ~2–3 days
  • WADA status: All components are prohibited at all times under “Anabolic Agents”.

Mechanism of Action

Testosterone Propionate

  • Esterified form of endogenous testosterone
  • Promotes protein synthesis, nitrogen retention and erythropoiesis
  • Aromatises to estradiol and converts to DHT

Drostanolone Propionate (Masteron P)

  • DHT-derived androgen with no aromatisation
  • Strong AR binding; low water-retention profile
  • May exhibit mild anti-estrogenic action at receptor level

Trenbolone Acetate

  • 19-nor testosterone derivative with extremely high AR affinity
  • Does not aromatise; interacts with progesterone receptors
  • Associated with strong anabolic effects and reduced glucocorticoid signalling

Together, these compounds produce additive or synergistic effects on androgen-mediated pathways while also accumulating their individual risk profiles.

Research Overview

Testosterone esters — studied extensively in hypogonadism, lean-mass changes, bone density and hematology.

Drostanolone — historically investigated in hormone-responsive breast cancer; displays typical DHT-like androgenic behaviour.

Trenbolone — widely documented in veterinary models; shows powerful anabolic, neuroendocrine, and metabolic effects.

Ripped 250 as a combined formulation lacks clinical trial data; research is based on extrapolation from individual components.

Potential Research-Level Observations

  • Enhanced protein synthesis and nitrogen retention
  • Marked changes in red blood cell mass and hemoglobin
  • Reduced fat mass and altered nutrient partitioning (trenbolone-related)
  • Increased muscle density and tissue “hardness” in controlled models

These findings apply only to research settings and do not imply suitability for unsupervised use.

Risk Profile & Possible Adverse Effects

Endocrine & Reproductive

  • Suppression of LH/FSH and endogenous testosterone
  • Testicular atrophy, reduced sperm count, infertility
  • Virilisation and menstrual disruption in females

Cardiovascular & Metabolic

  • Reduced HDL, increased LDL
  • Hypertension, fluid retention (via testosterone)
  • Increased risk of thrombotic or cardiovascular events
  • Polycythaemia (elevated hematocrit)

Hepatic & Renal

Potential hepatic strain despite being non-oral injectables

Renal stress secondary to blood-pressure alteration

Neuropsychiatric

Mood instability, irritability, anxiety

Insomnia or reduced impulse control

Other

  • Acne, seborrhoea, androgenic alopecia
  • Injection-site pain or infection
  • Gynecomastia risk due to testosterone aromatisation combined with trenbolone’s progestogenic action

Compliance & Regulatory Notice

All three ingredients are controlled/prescription-only substances in many jurisdictions.

WADA prohibits testosterone, drostanolone and trenbolone in- and out-of-competition.

Analytical detection windows vary depending on dose and duration.

This product is supplied strictly for laboratory and analytical research — not for therapeutic or recreational use.

Technical Data Table

ParameterValue
ParameterTest P
Mast PTren A
Chemical classAndrogen / AAS
DHT-derived AAS19-nor AAS
Concentration (mg/ml)100 mg
50 mg50 mg
EsterPropionate
PropionateAcetate
AromatisationYes
NoNo (progestogenic)
Half-life~2 days
~2 days~2–3 days
Main receptorAR, aromatase (indirect)
Androgen receptorAR & progesterone receptors
WADA statusProhibited
ProhibitedProhibited

For laboratory research only — not for human or veterinary use.

Characteristics
  • Concentration:
    250 mg/ml total (Test P 100 mg. Mast P 50 mg. Tren A 50 mg)
  • Country of manufacture:
    United Kingdom
  • Half-life:
    ~2 days
Reviews
No reviews yet
Write a review
Name*
Email
Enter your comment*